company background image
AERI

Aerie Pharmaceuticals NasdaqGM:AERI Stock Report

Last Price

US$15.12

Market Cap

US$746.8m

7D

-0.1%

1Y

28.2%

Updated

25 Sep, 2022

Data

Company Financials +
AERI fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health1/6
Dividends0/6

AERI Stock Overview

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States.

Aerie Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aerie Pharmaceuticals
Historical stock prices
Current Share PriceUS$15.12
52 Week HighUS$15.37
52 Week LowUS$4.81
Beta-0.055
1 Month Change0.20%
3 Month Change86.21%
1 Year Change28.24%
3 Year Change-25.66%
5 Year Change-68.89%
Change since IPO42.51%

Recent News & Updates

Aug 23

Alcon to acquire Aerie Pharmaceuticals at ~$770M, enhancing its ophthalmic pharmaceutical portfolio

Alcon (NYSE:ALC) to acquire Aerie Pharmaceuticals (NASDAQ:AERI) in a deal that values Aerie at ~$770M. The purchase price of $15.25/share represents a premium of 37% to Aerie’s last closing price and represents an equity value of ~$770M. The move builds on Alcon’s existing commercial expertise in the estimated $20B global ophthalmic pharmaceutical segment. Through the addition, Alcon will add Rocklatan® and Rhopressa®, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates. Rocklatan® is a fixed dose combination of the Rho kinase inhibitor, netarsudil, and a prostaglandin F2α analogue, latanoprost, indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Rhopressa® is a Rho kinase inhibitor indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. In most markets outside the U.S., commercialization rights for both products have been licensed to Santen SA and its affiliates. The transaction is expected to be accretive to Alcon’s core diluted EPS in 2024. The transaction was approved by the board of each company. The deal is anticipated to close in the fourth quarter of 2022. Alcon intends to fund the acquisition through short-term and long-term debt. Separately, Aerie’s most recent financial guidance for total glaucoma franchise net product revenue is $130M-140M for full year 2022.

Aug 15

Aerie Pharmaceuticals grants 16.9K stock options

Aerie Pharmaceuticals (NASDAQ:AERI) said one new employee was granted 16.9K stock options which will vest over four years. The company said the award was made outside of its stockholder-approved equity incentive plan and was approved by independent directors as an inducement material to the employee.

Shareholder Returns

AERIUS PharmaceuticalsUS Market
7D-0.1%-1.9%-5.2%
1Y28.2%2.9%-23.0%

Return vs Industry: AERI exceeded the US Pharmaceuticals industry which returned 2.9% over the past year.

Return vs Market: AERI exceeded the US Market which returned -23% over the past year.

Price Volatility

Is AERI's price volatile compared to industry and market?
AERI volatility
AERI Average Weekly Movement14.8%
Pharmaceuticals Industry Average Movement11.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: AERI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: AERI's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2005376Raj Kannanhttps://www.aeriepharma.com

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases.

Aerie Pharmaceuticals, Inc. Fundamentals Summary

How do Aerie Pharmaceuticals's earnings and revenue compare to its market cap?
AERI fundamental statistics
Market CapUS$746.80m
Earnings (TTM)-US$49.42m
Revenue (TTM)US$207.13m

3.6x

P/S Ratio

-15.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AERI income statement (TTM)
RevenueUS$207.13m
Cost of RevenueUS$24.49m
Gross ProfitUS$182.64m
Other ExpensesUS$232.06m
Earnings-US$49.42m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.00
Gross Margin88.18%
Net Profit Margin-23.86%
Debt/Equity Ratio-221.2%

How did AERI perform over the long term?

See historical performance and comparison